The European Medicines Evaluation Agency.
作者信息
Herxheimer A
出版信息
BMJ. 1996 Feb 17;312(7028):394. doi: 10.1136/bmj.312.7028.394.
Abstract
摘要
相似文献
1
The European Medicines Evaluation Agency.欧洲药品评估局
BMJ. 1996 Feb 17;312(7028):394. doi: 10.1136/bmj.312.7028.394.
2
Pharmaceutical regulation in the single European market.单一欧洲市场的药品监管
Med Law. 1998;17(3):401-27.
3
European ombudsman questions European Medicines Agency over AbbVie redactions.欧洲申诉专员就艾伯维公司的删节内容质问欧洲药品管理局。
BMJ. 2014 Nov 18;349:g6904. doi: 10.1136/bmj.g6904.
4
Medicines to remain with European Commission health directorate.药品将留在欧盟委员会卫生司。
BMJ. 2014 Oct 29;349:g6514. doi: 10.1136/bmj.g6514.
5
Pathways to faster access to medicines.更快获取药品的途径。
Drug Ther Bull. 2018 Aug;56(8):93-96. doi: 10.1136/dtb.2018.8.0660.
6
[EURO-Medicines: a European program for bringing into agreement public health policies on drugs].[欧洲药品计划：一项使欧洲各国在药品公共卫生政策上达成一致的计划]
Ann Ig. 1998 Sep-Dec;10(5-6):405-12.
7
Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.欧盟《儿童用药规例》下临床试验完成和结果报告的延误：一项队列研究。
PLoS Med. 2018 Mar 1;15(3):e1002520. doi: 10.1371/journal.pmed.1002520. eCollection 2018 Mar.
8
Future of the European Union regulatory network in the context of the uptake of new medicines.新药品应用背景下欧盟监管网络的未来。
Br J Clin Pharmacol. 2013 Jul;76(1):1-6. doi: 10.1111/j.1365-2125.2012.04476.x.
9
[European registration of medicines: pros and cons for prescriber and patient].[欧洲药品注册：对开处方者和患者的利弊]
Ned Tijdschr Geneeskd. 1997 May 24;141(21):1028-33.
10
[European drug policy].[欧洲毒品政策]
Bull Mem Acad R Med Belg. 1993;148(5-6):207-12; discussion 212-6.
引用本文的文献
1
Risk minimization activities of centrally authorized products in the EU: a descriptive study.在欧盟中对集中授权产品的风险最小化活动：一项描述性研究。
Drug Saf. 2012 Apr 1;35(4):299-314. doi: 10.2165/11594560-000000000-00000.
2
Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.欧洲药品评估局批准的新药儿科用药情况。
Br J Clin Pharmacol. 1999 Jul;48(1):15-8. doi: 10.1046/j.1365-2125.1999.00981.x.
3
The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.欧洲药品评估局：饱受批评。透明度必须与更高的严谨性相结合。
BMJ. 1998 Oct 3;317(7163):898. doi: 10.1136/bmj.317.7163.898.
Zotero 插件